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ABSTRACT
Objectives Congestion can worsen outcomes after 
transcatheter aortic valve implantation (TAVI), but can be 
difficult to quantify non- invasively. We hypothesised that 
preprocedural plasma volume status (PVS), estimated 
using a validated formula that enumerates percentage 
change from ideal PV, would provide prognostic utility 
post- TAVI.
Methods This retrospective cohort study identified 
patients who underwent TAVI (2007–2017) from a 
prospectively collected database. Actual ([1- haematocrit] 
× [a + (b × weight (Kg))] and ideal (c × weight (Kg)) PV 
were quantified from equations where a, b and c are sex- 
dependent constants. Calculated PVS was then derived 
(100% x [(actual – ideal PV)/ideal PV]).
Results In 564 patients (mean age 82±7 years, 49% 
male), mean PVS was −2.7±10.2%, with PV expansion 
(PVS >0%) evident in 39%. Only logistic European System 
for Cardiac Operative Risk Evaluation (EuroSCORE) 
independently predicted a PVS >0% (OR 1.85, p=0.002). 
On Cox analyses, a PVS >0% was associated with greater 
mortality at 3 (HR 2.29, 95% CI 1.11 to 4.74, p=0.03) and 
12 months (HR 2.00, 95% CI 1.23 to 3.26, p=0.006) after 
TAVI, independently of, and incremental to, the EuroSCORE 
and New York Heart Association class. A PVS >0% was 
also independently associated with more days in intensive 
care (coefficient: 0.41, 95% CI 0.04 to 0.78, p=0.03) and in 
hospital (coefficient: 1.95, 95% CI 0.48 to 3.41, p=0.009).
Conclusion Higher PVS values, calculated simply from 
weight and haematocrit, are associated with greater 
mortality and longer hospitalisation post- TAVI. PVS could 
help refine risk stratification and further investigations into 
the utility of PVS- guided management in TAVI patients is 
warranted.
INTRODUCTION
Transcatheter aortic valve implantation 
(TAVI) is the standard of care for patients 
with severe aortic stenosis who are at high or 
prohibitive surgical risk. In patients at low or 
intermediate risk, TAVI is at least non- inferior 
to surgical aortic valve replacement.1 2 TAVI 
use is increasing worldwide3 and the move 
towards conscious sedation, smaller delivery 
systems and improved vascular closure tech-
niques have facilitated earlier discharge 
with potential cost savings. Despite these 
refinements, however, in- hospital and 1- year 
mortality rates after TAVI are ~3% and 22%, 
respectively,3 underscoring the need for novel 
remediable markers of adversity after TAVI.
Congestion is a powerful predictor of 
adverse outcomes in many clinical settings, 
especially perioperatively4 5 and heart failure 
before TAVI is associated with adverse clinical 
outcomes.6 While overt congestion is easy to 
detect, many cardiac patients are haemody-
namically overloaded despite clinical euvo-
laemia (covert congestion), and the prognosis 
for these individuals is nearly as bad as for 
those with overt oedema.7–9 Novel markers of 
congestion that can accurately detect subclin-
ical congestion have potential to provide 
Key questions
What is already known about this subject?
 ► Congestion predicts adverse outcomes in many clin-
ical settings, especially perioperatively.
 ► Many patients with cardiac disease remain haemo-
dynamically overloaded despite clinical euvolaemia.
 ► Plasma volume status (PVS) can be estimated using 
a validated formula, incorporating simple clinical in-
dices (weight and haematocrit), which enumerates 
percentage change from ideal plasma volume.
What does this study add?
 ► In transcatheter aortic valve implantation (TAVI) pa-
tients, congestion (as signified by PVS >0%) associ-
ates with mortality.
 ► In TAVI patients, PVS >0% associates with longer 
duration of hospitalisation.
How might this impact on clinical practice?
 ► Calculated PVS may have additive value if incorpo-
rated into risk stratification models.
 ► PVS- guided fluid management in TAVI patients war-
rants further investigation.
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incremental prognostic information, when considered 
alongside other predictors of clinical outcomes in TAVI 
patients.10–13 Accurate markers of congestion may also 
help guide diuretic therapy prior to TAVI.
Plasma volume (PV) expansion underlies systemic 
congestion in cardiac patients and can be objectively 
estimated using validated equations based on weight 
and haematocrit.14 15 In prior studies, calculated PV 
levels were shown to mirror those measured using gold 
standard radioisotope assays.16 17 Moreover, relative PV 
status (PVS), a measure of the degree to which patients 
have deviated from their ideal PV, predicted mortality in 
various heart failure cohorts,16–19 and in patients under-
going coronary artery bypass grafting.20
In the present analysis, we tested the hypothesis that 
preprocedural cardiac congestion, detected by a higher 
preprocedure PVS, would predict a longer duration of 
hospitalisation, longer stay on the intensive care unit 
(ICU) and a greater risk of mortality after TAVI.
METHODS
Population
Consecutive patients who underwent TAVI at King’s 
College Hospital London between August 2007 and 
March 2017 were identified from an approved prospec-
tively collected national registry database, which was 
retrospectively studied. Patient demographics, proce-
dural characteristics, duration of hospitalisation and 
procedural outcomes were recorded prospectively onto 
the registry, and reported according to Valve Academic 
Research Consortium-2 criteria.21 All- cause mortality was 
ascertained from the registry and verified from hospital 
information systems that are regularly updated with 
deaths from the Office of National Statistics. The need 
for individual patient informed consent was waived by the 
local research office as this was a retrospective analysis 
using a de- identified database.
Each patient was selected for TAVI by a multidisciplinary 
Heart Team, attended by interventional and imaging 
cardiologists, cardiothoracic surgeons and cardiac 
anaesthetists. The patients selected for TAVI were either 
formally turned down for surgical aortic valve replace-
ment by two cardiothoracic surgeons, or were deemed 
too high- risk for surgical aortic valve replacement. From 
2007 to 2012, patients were routinely monitored on ICU 
post- TAVI. After October 2012, patients were cared for 
on a level- two unit post- TAVI and not in ICU. Of the 576 
patients in the database, 10 were excluded because of 
missing weights and two were excluded due to missing 
haematocrits. Thus, 564 patients were included in this 
study. In- hospital weights and haematocrits documented 
just before TAVI were used to calculate PVS.
PV equations
Actual PV was calculated with the following equation, 
derived by curve- fitting techniques using the partici-
pants' haematocrit and weight compared with PV values 
measured with the gold standard radiolabelled albumin 
assay.16
 actual PV = (1 − haematocrit) × (a + [b × weight(Kg)]) 
where haematocrit is a fraction, and a=1530 in males 
and 864 in females, and b=41 in males and 47.9 in females.
Ideal PV was calculated from the following established 
formula17 :
 ideal PV = c × weight (Kg) 
where c=39 in males and 40 in females.
Relative PVS, an index of the degree to which patients 
have deviated from their ideal PV, was subsequently calcu-
lated from the following equation:
 PVS = ([actual PVideal PV]/ ideal PV) × 100%. 
Statistical analysis
Data are presented as proportions (%), mean±SD or 
medians (IQR. Intergroup comparisons were made using 
Figure 1 Distribution of plasma volume status (PVS) (A), 
and shape of relation of PVS to in- hospital mortality (B) and 
days in hospital (C) grey shaded area in (B) and (C) denotes 
the 95% CI.
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Age, years 82±7 82±7 83±7 0.23
Male sex 277 (49) 160 (46) 117 (53) 0.10
Body mass index, kg/m2 26 (23 to 30) 28 (25 to 32) 24 (21 to 27) <0.001
Logistic EuroSCORE 14 (10 to 23) 13 (9 to 21) 16 (10 to 26) 0.002
Canadian cardiovascular society angina class ≥III 6 (1) 3 (1) 3 (1) 0.68
NYHA class ≥III* 365 (65) 218 (63) 147 (67) 0.36
Diabetes mellitus 125 (22) 76 (22) 49 (22) 0.92
Hypertension* 440 (79) 274 (79) 166 (77) 0.41
Renal failure†* 17 (3) 6 (2) 11 (5) 0.03
Pulmonary disease* 136 (24) 86 (25) 50 (23) 0.55
Peripheral vascular disease 118 (21) 61 (18) 57 (26) 0.02
Atrial fibrillation/ flutter 151 (27) 101 (29) 50 (23) 0.09
Prior cerebrovascular accident* 42 (8) 26 (8) 16 (7) 0.94
Prior myocardial infarction* 49 (9) 31 (9) 18 (8) 0.74
Prior cardiac surgery* 126 (22) 71 (21) 55 (25) 0.20
Previous percutaneous coronary intervention* 99 (18) 67 (19) 32 (15) 0.15
Left ventricular ejection fraction, n (%)* 0.29
  Good (ejection fraction ≥50%) 387 (69) 241 (71) 146 (68)
  Fair (ejection fraction 30%–49%) 149 (27) 85 (25) 64 (30)
  Poor (ejection fraction <30%) 22 (4) 16 (5) 6 (3)
Coronary artery disease 171 (30) 98 (29) 73 (33) 0.24
  Triple vessel disease 46 (8) 30 (9) 16 (7) 0.54
Aortic valve pathology* 0.53
  Aortic stenosis 533 (95) 328 (96) 205 (95)
  Aortic regurgitation 13 (2) 6 (2) 7 (3)
  Mixed aortic valve disease 14 (3) 9 (3) 5 (2)
Severe aortic calcification* 287 (55) 190 (59) 97 (48) 0.02
Mean aortic gradient, mm Hg* 42±16 41±16 44±16 0.02
Peak aortic gradient, mm Hg* 75±25 73±25 79±25 0.01
Aortic valve area, cm2* 0.7 (0.6 to 0.8) 0.7 (0.6 to 0.9) 0.7 (0.5 to 0.8) 0.07
Aortic annulus, mm* 24 (22 to 25) 23 (22 to 25) 24 (22 to 25) 0.38
Creatinine, µmol/L* 94 (74 to 115) 93 (74 to 11) 96 (76 to 118) 0.21
Estimated glomerular filtration rate, mL/min* 60 (46 to 76) 61 (47 to 77) 60 (46 to 75) 0.36
Haemoglobin, g/L 120±18 127±17 110±13 <0.001
Calculated actual PV (mL) 2730±501 2753±509 2693±487 0.17
Calculated actual PV (mL/kg) 38±4 36±3 42±2 <0.001
Ideal PV (mL), mean±SD 2842±627 3042±623 2527±488 <0.001
PVS, % −3±10 −9±7 7±6 ---
Valve type* <0.001
  Sapien XT 199 (36) 121 (35) 78 (36)
  Sapien 3 240 (43) 159 (47) 81 (37)
  Sapien 69 (12) 24 (7) 45 (21)
  Other (eg, Lotus, Portico) 52 (9) 37 (11) 15 (7)
Continued
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a Student’s t- test, Mann- Whitney U test, Pearson χ2 test 
or Fisher’s exact test as appropriate. The distribution of 
continuous variables was visually assessed.
Associations between PVS and baseline covariates, 
lengths of stay and postprocedural complications were 
evaluated using univariable and multivariable linear or 
logistic regression. For baseline correlates of PVS, multi-
variable regression only included covariates that differed 
between patients who did and did not have PV expansion 
(ie, PVS>0%), and that were not directly related to the 
European System for Cardiac Operative Risk Evaluation 
(EuroSCORE) so as to minimise collinearity. For the asso-
ciation of PVS to lengths of stay and complications, multi-
variable models only adjusted for a priori determined 
clinically relevant covariates (EuroSCORE and NYHA 
(New York Heart Association) class) to minimise collin-
earity and prevent model overfitting. A p<0.20 was used 
to enter and retain covariates in multivariable models. 
The validity of linear and logistic regressions was verified 
by analysis of model residuals, linearity condition, testing 
for heteroscedasticity and the absence of interaction 
and multicollinearity. k- fold cross- validation was used to 
quantify overfitting. As lengths of stay were not normally 
distributed, bootstrap linear regression with 1000 boot-
strap samples was performed to model these endpoints.
Association between PVS and all- cause death was deter-
mined using univariable and multivariable Cox propor-
tional hazards regression. Multivariable Cox models only 
included PVS, EuroSCORE and NYHA class to minimise 
collinearity and prevent model overfitting. The signif-
icance levels for chi- square (likelihood ratio test) were 
calculated. The validity of Cox models was verified by 
assessing the proportionality of hazards, log- linearity, 
and absence of interaction and multicollinearity. Kaplan- 
Meier cumulative survival plots were constructed for visu-
alisation and assessed using the log- rank test.
Calculated PVS was assessed as both a continuous 
and categorical variable. The shape of the associa-
tion between PVS and outcomes was investigated by 
constructing restricted cubic spline plots on the PVS 
function. The PVS cut- off that best discriminated 
mortality was determined using receiver operating 
characteristics analysis. In this, sensitivity and speci-
ficity were of equal importance, therefore, the optimal 
PVS cut- off was the one giving the highest Youden 
index. The incremental predictive ability of PVS was 
evaluated by calculating the continuous net reclassifi-
cation improvement and the integrated discrimination 
index. To facilitate this for the analysis of hospital stay, 








Valve delivery approach* 0.002
  Femoral—percutaneous 325 (58) 216 (63) 109 (50)
  Femoral—surgical cut down 95 (17) 56 (16) 39 (18)
  Transapical 140 (25) 69 (20) 71 (32)
  Other 3 (1) 3 (1) 0
Valve size, mm* 26 (23 to 26) 26 (23 to 26) 26 (23 to 26) 0.71
Volume of contrast, mL* 100 (60 to 120) 100 (65 to 120) 100 (60 to 130) 0.71
Vascular closure technique* 0.007
  Percutaneous 324 (58) 213 (62) 111 (51)
  Surgical 237 (42) 129 (38) 108 (49)
Valve- in- valve procedure* 26 (5) 17 (5) 9 (4) 0.64
Blood transfusion* 108 (19) 43 (13) 65 (30) <0.001
Anaesthesia 0.29
  General anaesthesia 489 (87) 295 (86) 194 (89)
  Conscious sedation 75 (13) 50 (14) 25 (11)
Data are n (%), mean±SD, or median (IQR).
P- values <0.05 are highlighted in bold
*Missing values: aortic valve area, 16; aortic valve pathology, 4; blood transfusion, 3; creatinine, 1; coronary artery disease, 3; 
estimated glomerular filtration rate, 1; EuroSCORE, 23; haemoglobin, 23; hypertension, 2; left ventricular ejection fraction, 6; mean 
aortic gradient, 24; NYHA class, 1; peak aortic valve gradient, 6; previous cardiac surgery, 1; ; previous cerebrovascular accident, 
2; previous myocardial infarction, 2; previous percutaneous coronary intervention, 4; pulmonary disease, 2; renal failure, 2; severe 
aortic calcification, 41; vascular closure technique, 3; valve delivery approach, 1; valve- in- valve procedure, 3; valve size, 1; valve 
type, 4; volume of contrast, 42.
†Creatine >200 umol/L or on dialysis.
EuroSCORE, European System for Cardiac Operative Risk Evaluation; NYHA, New York Heart Association; PV, plasma volume; 
PVS, plasma volume status.
Table 1 Continued
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long- stayers if they stayed above the median, or short- 
stayers if they did not.
Only 1.6% of the total data was missing and survival 
analyses with and without imputation showed consistent 
results. No adjustments for multiple statistical compari-
sons were made. Data were analysed using SPSS (V.25.0, 
SPSS, IBM) and STATA (V.12, StataCorp). A two tailed 
p<0.05 was considered statistically significant.
RESULTS
Population and procedural characteristics
The baseline and procedural characteristics of the 
564 TAVI patients are shown (table 1). Calculated PVS 
appeared to have a normal distribution and ranged from 
−38.0% to 26.8% (figure 1A).
Relative PV expansion, as defined by a PVS >0%, was 
evident in 39% of all patients, and in 35% and 42% of 
all female and male subjects, respectively. Compared with 
all patients with a PVS ≤0%, those with a PVS >0% were 
more likely to have a lower body mass index, a logistic 
EuroSCORE above the median (>14), renal failure, 
peripheral vascular disease, severe aortic valve calcifica-
tion, higher mean and peak aortic valve gradients and a 
lower haemoglobin. On multivariable logistic regression, 
only a EuroSCORE >14 (OR 1.83, 95% CI 1.27 to 2.62, 
p<0.001) independently predicted a PVS >0%.
PVS and mortality after TAVI
After a median hospital stay of 8 (IQR: 3–8) days, 22 
(3.9%) patients died in hospital, and 26 (4.6%), 35 
(6.2%) and 70 (12.4%) died at 1, 3 and 12 months post- 
TAVI, respectively. The relation between PVS and the log 
relative hazard for mortality was non- linear and generally 
‘J- shaped’ (figure 1B) at all timepoints. Consequently, 
PVS was dichotomised using a >0% cut- off as it gave the 
highest Youden index for discriminating death at all 
timepoints. A PVS >0% was associated with an increased 
risk for death at 3 and 12 months after TAVI, but not 
with inpatient death or mortality at 1 month (table 2) 
(figure 2A). After adjustment, a PVS >0% was linked 
to a two- fold heightened risk for mortality at 3 and 12 
months, respectively. In a landmark analysis excluding 
patients who had died by 30 days, a PVS >0% related to 
12- month mortality.
Addition of PVS >0% to a baseline model incorpo-
rating EuroSCORE >14 and NYHA class ≥III incremented 
model performance as it enabled 11% (95% CI −13% 
to 35%) of patients dying at 12 months to be correctly 
reclassified as higher risk, and 28% (95% CI 18% to 37%) 
of patients surviving to 12 months to be reclassified as 
lower risk. The overall net reclassification improvement, 
reflecting the increment in prediction accuracy, was 0.40 
(95% CI 0.12 to 0.66). The integrated discrimination 
index, which reflects the change in calculated risk for 
each patient was 0.011 (95% CI −0.002 to 0.037) among 
patients who died, and 0.001 (95% CI −0.000 to 0.005) 
for patients who survived. The discrimination slope was 
1.2 (95% CI −0.2% to 4.2%) percentage points higher 
than the original.
PVS and post-TAVI hospitalisation and complications
Median ICU stay (in the total population) and total 
hospital stay (in patients discharged alive) was 1 (IQR: 
0–1) and 5 (IQR 3–8) days, respectively. The relation 
between PVS and the duration of ICU and hospital stay 
was essentially linear between PVS values of −15% to 15% 
(figure 1C). Higher levels of PVS were related to longer 
ICU and hospital stay, and remained so after adjust-
ment for EuroSCORE >14 and NYHA class ≥III (table 2). 
Accordingly, patients with a PVS>0% stayed in the ICU 
and hospital longer after TAVI, compared with patients 
with a PVS≤0% (figure 2B). A PVS>0% was associated 
Table 2 Association of PVS>0% and continuous PVS to deaths and lengths of hospital and intensive care unit stay
Outcome Crude HR (95% CI) P value
Adjusted HR *
P value(95% CI)
PVS >0% In- hospital mortality 1.46 (0.58 to 3.68) 0.43 1.15 (0.44 to 2.96) 0.78
  1- month mortality 2.04 (0.89 to 4.65) 0.09 1.77 (0.77 to 4.07) 0.18
  3- month mortality 2.61 (1.28 to 5.35) 0.008 2.29 (1.11 to 4.74) 0.03
  12- month mortality 2.20 (1.35 to 3.58) 0.001 2.00 (1.23 to 3.26) 0.006
  12- month mortality (landmark) 2.35 (1.29 to 4.28) 0.005 2.18 (1.19 to 3.99) 0.01
  Outcome Crude regression coefficient (95% CI) P value Adjusted * regression 
coefficient (95% CI)
P value
    
PVS Days in the intensive care unit 0.02 (0.00 to 0.04) 0.01 0.02 (0.00 to 0.04) 0.04
  Days in hospital 0.14 (0.08 to 0.21) <0.0001 0.12 (0.06 to 0.17) <0.0001
    
PVS >0% Days in the intensive care unit 0.48 (0.10 to 0.85) 0.01 0.41 (0.04 to 0.78) 0.03
  Days in hospital 2.56 (1.03 to 4.10) 0.001 1.95 (0.48 to 3.41) 0.009
*Adjusted for EuroSCORE >14 and NYHA class ≥3.
EuroSCORE, European System for Cardiac Operative Risk Evaluation; NYHA, New York Heart Association; PVS, plasma volume status.
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with 0.4 and 2 extra days in ICU and in hospital, respec-
tively, after covariate adjustment (table 2). Addition of 
continuous PVS to the baseline model enhanced model 
performance as it enabled 16% (95% CI −7% to 27%) of 
hospital long stayers to be correctly reclassified as long 
stayers, and 14% (95% CI 5% to 25%) of short stayers 
to be reclassified as short stayers. The overall net reclas-
sification improvement was 0.29 (95% CI 0.16 to 0.49). 
The integrated discrimination index for each patient 
was 0.015 (95% CI 0.005 to 0.033) among long stayers 
and 0.014 (95% CI 0.004 to 0.031) for short stayers. The 
discrimination slope was 3.0 (95% CI 0.9% to 4.2%) 
percentage points higher than the original.
TAVI was complicated by acute kidney injury (stage II 
or III), cerebrovascular accident, pacemaker implanta-
tion and major vascular injury in 3%, 1%, 8% and 3% 
of patients, respectively. In unadjusted analyses, contin-
uous PVS was not associated with the risk of acute kidney 
injury (OR 1.04, 95% CI 1.00 to 1.08, p=0.05), cerebro-
vascular accident (OR 1.03, 95% CI 0.92 to 1.16, p=0.58), 
pacemaker implantation (OR 1.02, 95% CI 0.99 to 1.05, 
p=0.27) or major vascular injury (OR 1.00, 95% CI 0.96 
to 1.05, p=0.91). Similarly, a PVS >0% was not associated 
with the risk of acute kidney injury (OR 1.83, 95% CI 
0.88 to 3.84, p=0.11), cerebrovascular accident (OR 3.14, 
95% CI 0.28 to 34.87, p=0.35), pacemaker implantation 
(OR 1.10, 95% CI 0.59 to 2.05, p=0.77) or major vascular 
injury (OR 0.47, 95% CI 0.15 to 1.47, p=0.20).
DISCUSSION
Patient optimisation facilitates good TAVI outcomes, 
and congestion is a correctable adverse factor that can 
be substantial despite clinical euvolaemia. Using only 
weights and haematocrits, we evaluated the utility of PVS, 
a quantitative index of relative volume overload, in TAVI 
patients. We found that: (1) a relative increase in PV (as 
defined by a PVS >0%) was present in 39% of patients; 
(2) a higher logistic EuroSCORE was independently 
correlated with a PVS >0% and (3) a PVS >0% identified 
patients at a heightened risk for mortality and prolonged 
ICU and hospital stay.
Calculated PVS values suggest that our TAVI patients 
were more congested than stable outpatients with systolic 
heart failure. This is because mean PVS in our cohort was 
−3% which is higher (ie, more congested) than the −9% 
reported in 5002 outpatients with chronic heart failure 
with reduced ejection fraction (HFrEF).16 This is clinically 
plausible and likely reflects the fact that TAVI patients 
are sicker, commonly have HFrEF or heart failure with 
preserved ejection fraction (HFpEF) and are frequently 
on suboptimal doses of heart failure drugs due to blood 
pressure and/or renal function limitations. Indeed, 
higher doses of prognostic medications are linked to 
higher odds of having an optimal PVS in patients with 
HFrEF.17
That a higher logistic EuroSCORE was the only inde-
pendent correlate of PV expansion likely mirrors the fact 
that it is derived from many variables that drive conges-
tion. This includes left ventricular systolic dysfunction, 
diabetes, a critical preprocedural clinical status, pulmo-
nary hypertension and renal dysfunction. Despite this 
association, however, a PVS >0% provided prognostic 
information that was independent and complementary 
to that offered by the EuroSCORE. It is important to note 
that only 3% of our cohort had renal failure (defined 
as creatinine >200 μmol/L or requiring dialysis), and it 
is conceivable that if the number of patients with renal 
failure were larger, it may have been a multivariable 
predictor pf PVS >0%.
Calculated PV expansion related to worse outcomes 
after TAVI, in line with prior data in chronic HFrEF 
patients16 17 19 and other cohorts18 20 22 In 1887, patients 
undergoing coronary artery bypass grafting, a preop-
erative PVS ≥5.6% was linked to a twofold increase in 
in- hospital mortality, longer hospital stays and greater 
postoperative renal and arrhythmic complications.20 In 
3414 HFpEF patients, each 5% increment in PVS was asso-
ciated with an ~11% higher risk of death or heart failure 
hospitalisation.19 Moreover, in 1115 patients hospitalised 
for acute HFrEF, each 1% increment in admission PVS 
forecasted a 21% increased risk for death.18
Figure 2 Kaplan Meier survival curve for calculated plasma 
volume status (PVS) stratified by PVS ≤0% and PVS >0% (A), 
and duration of hospitalisation after TAVI in patients alive at 
discharge stratified by PVS ≤0% and PVS >0% (B). The solid 
line in (A) denotes survival probability and the shaded area 
in (A) represents the 95% CI. The p value in (B) is calculated 
from the Mann- Whitney U test. TAVI, transcatheter aortic 
valve implantation.
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In a cohort of 652 TAVI patients, PVS ≥4 was associated 
with all- cause mortality in the longer term and was associ-
ated with a 30- day composite of all- cause mortality, stroke, 
life- threatening bleeding, acute kidney injury, coronary 
artery obstruction requiring intervention, major vascular 
complication and valve related dysfunction requiring repeat 
procedure.22 However, PVS ≥4 was not associated with the 
primary endpoint for that study,22 that is, 30- day mortality, 
and until now the findings have not undergone external 
validation in an independent cohort. Our study builds on 
previous data, by independently validating the association 
between elevated PVS and mortality, and showing that PVS 
>0% is associated with prolonged ICU stay.
The adverse implications of a PVS >0% in TAVI 
patients most likely reflects the ominous consequences 
of PV expansion in a cohort with stiff non- compliant 
ventricles. This further exaggerates increases in intra-
vascular filling pressures per unit change in ventricular 
volumes, leading to a greater propensity to pulmonary 
and systemic oedema, multiorgan hypoperfusion and 
adverse outcomes after TAVI. Alternatively, it could be 
argued that the PVS equation does not truly gauge PV 
but merely reflects the prognostic implications of weight 
and haematocrit, or other factors in TAVI cohorts that 
modulate these variables. For example, patients with PVS 
>0% had lower body mass index, potentially reflecting 
frailty, which is known to predict long- term mortality after 
TAVI.11 However, calculated PV levels have been shown to 
correlate well to PV levels measured using gold- standard 
radioisotope assays,16 17 and calculated PVS is known to 
remain prognostic even after extensive covariate adjust-
ment including for natriuretic peptides.16–19
Our results should be interpreted in the context of 
study limitations. First, this is an observational study, so 
causality cannot be inferred. Second, the median length 
of hospitalisation in our cohort is relatively long as it 
included patients who had TAVI as far back as 2007, 
whereas, in the current era, duration of hospitalisation 
is on average shorter due to improvements in patient 
selection and technical advances. Third, information 
on natriuretic peptides and clinical signs of congestion 
was unavailable. Fourth, even though patients with PVS 
>0% had higher incidence of blood transfusions and 
transapical approach during TAVI, and we expected to 
observe higher short- mortality in this group of patients, 
the relatively small number of deaths in hospital and by 
30 days post- TAVI limited the power to detect statistically 
significant mortality differences at this timepoint. Simi-
larly, few patients had acute kidney injury stage II or III 
following TAVI, so we are likely underpowered for this 
endpoint.
Despite limitations, our study has potentially important 
ramifications. First, it suggests that calculated PVS might 
be of clinical utility in guiding objective fluid manage-
ment decisions before and after TAVI. Diuretic and non- 
diuretic therapy could then be titrated to keep PVS≤0% 
irrespective of apparent clinical euvolaemia. Because 
calculated PVS relies only on weight and haematocrit, 
it provides a potentially simple non- invasive means of 
gauging congestion that could have wide applicability. 
Second, our data justify incorporation of PVS into risk- 
stratification models in patients undergoing TAVI, 
which could potentially help identify patients for early 
discharge, or for more intensive monitoring after TAVI. 
Third, our data suggest that further observational and 
interventional studies may be warranted to objectively 
determine the clinical utility of PVS- guided optimisation 
of TAVI patients. We did not measure PVS after TAVI, 
hence it was not possible to measure change in PVS 
after the procedure relative to baseline, which might be 
relevant for future research, because the relief of aortic 
stenosis would be expected to reduce PVS.
In conclusion, a PVS >0%, calculated simply from weight 
and haematocrit, is associated with a higher logistic Euro-
SCORE, but independently and incrementally predicts an 
increased risk of mortality and prolonged hospitalisation 
after TAVI. Prospective evaluation of the utility of calculated 
PVS- guided optimisation of TAVI patients is warranted.
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